ArticleKidney3602026
Association between Maternal Midterm eGFR and Newborn Birth Weight: Seiiku Boshi Cohort Study.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
key pointsLower maternal midterm eGFR was independently associated with increased risks of low birth weight and small for gestational age. Adding eGFR to conventional risk models improved prediction of adverse birth outcomes, highlighting its value as a prognostic marker. Midterm eGFR assessment may help identify at-risk pregnant women without overt disease, allowing closer monitoring and timely intervention.
backgroundLittle is known regarding whether renal function during pregnancy among healthy women is associated with pregnancy outcomes. Evidence based on the universal screening of maternal eGFR is lacking. We investigated the association of maternal eGFR during the second trimester with fetal birth weight.
methodsThis prospective birth cohort study includes 1666 singleton pregnant women (median age 36 years, median body mass index 20.0) who had universal screening of eGFR during the second trimester. Participants were categorized into the quartile of eGFR. The first quartile group was defined as low eGFR, the fourth quartile group as high eGFR, and the second and third quartile group as reference. The primary outcomes are low birth weight (LBW) and small for gestational age (SGA). Multivariable logistic regression models were used to investigate the association of maternal eGFR and pregnancy outcomes.
resultsAs compared with the reference group, the adjusted odds ratios (95% confidence intervals [CIs]) for LBW and SGA in the low eGFR group were 2.25 (1.48 to 3.40) and 2.51 (1.63 to 3.87), respectively, and in the high eGFR group were 0.69 (0.40 to 1.19) and 0.55 (0.30 to 1.02), respectively. The adjusted odds ratios of eGFR per SD decrease (95% CI) for LBW and SGA were 1.92 (1.50 to 2.45; P = 0.013) and 2.07 (1.60 to 2.68; P < 0.001). The prediction models were improved by adding eGFR to the models including covariates for LBW (C statistics difference, +0.018; 95% CI, -0.004 to 0.040, net reclassification improvement;, 0.377; 95% CI, 0.208 to 0.545, and integrated discrimination improvement, 0.0135; 95% CI, 0.005 to 0.022) and for SGA (C statistics difference, +0.041; 95% CI, 0.003 to 0.080; net reclassification improvement, 0.408; 95% CI, 0.226 to 0.591; and integrated discrimination improvement, 0.017; 95% CI, 0.009 to 0.025).
conclusionsThe lower maternal midterm eGFR is associated with LBW and SGA, while the higher eGFR is not. Evaluating midterm eGFR may help identify healthy women at risk of adverse birth outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.